“Frontline DNA-Repair Inhibition As Maintenance in High-Risk Ovarian Carcinoma”. International Journal of Clinical Research and Medical Sciences, vol. 1, no. 3, Oct. 2026, https://doi.org/10.67231/4gks8p50.